Results 1 to 10 of about 23,498 (195)
Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation [PDF]
PLoS ONE, 2016 The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV ...A Bellizzi, A Laroni, A Petrovic, Ada Francia, Alessandra D’Abramo, Alessandra Oliva, Anna Bellizzi, B Engelhardt, BL Padgett, C Bozic, C Tornatore, Claudia D’Agostino, Claudio Maria Mastroianni, D Jing, E Pucci, Elena Anzivino, EM Frohman, EM Johnson, Enrico Millefiorini, EO Major, EO Major, F Serana, F Taguchi, G Defer, H Bonig, K Khalili, L Börnsen, L Gorelik, LJ Marshall, M Niino, Manuela Morreale, Marco Iannetta, Maria Antonella Zingaropoli, Maria Rosa Ciardi, MC Monaco, ME Hemler, P Maenetje, RA Rudick, RM Ransohoff, Robert Shin Fujinami, RR Lobb, S Beltrami, SA Houff, SA Sadiq, Sara Lo Menzo, Simona Pontecorvo, T Van Loy, Valeria Pietropaolo, Vincenzo Vullo, WJ Atwood, Y Chen, Ö Yaldizli +51 morecore +5 more sourcesNatalizumab (Tysabri) [PDF]
American Journal of Neuroradiology, 2010 Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.D T, Selewski, G V, Shah, B M, Segal, P A, Rajdev, S K, Mukherji +4 moreopenaire +2 more sourcesA systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. [PDF]
, 2020 Neurologists managing women with Multiple Sclerosis (MS) need information about the safety of disease modifying drugs (DMDs) during pregnancy. However, this knowledge is limited.A Haghikia, AL Nguyen, C Weber-Schoendorfer, D Moher, E Lu, E Lu, E Portaccio, G Comi, HV De Las, J Thone, JP Higgins, L Shamseer, MK Houtchens, N Ebrahimi, PK Coyle, R Alroughani, R Boskovic, S Herbstritt, S Pernia, S Thiel, SC MacDonald +20 morecore +1 more sourceThe still under-investigated role of cognitive deficits in PML diagnosis [PDF]
, 2017 Background: Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in PML diagnosis is still under ...Amato, Maria Pia, Artusi, Carlo Alberto, Bandini, Fabio, Barcella, Valeria, Bertolotto, Antonio, Bresciamorra, Vincenzo, Capobianco, Marco, Capra, Ruggero, Cavaletti, Guido, Cavalla, Paola, Centonze, Diego, Clerico, Marinella, Cordioli, Cinzia, Cosottini, Mirco, D'Aleo, Giangaetano, de Riz, Marilena, De Rossi, Nicola, Deotto, Luciano, Durelli, Luca, Falcini, Mario, Ferrari, Ernesta, Fusco, Maria Luisa, Gasperini, Claudio, Gerevini, Simonetta, Ghezzi, Angelo, Grimaldi, Luigi, Guidotti, Mario, Laroni, Alice, Lugaresi, Alessandra, Mattioli, Flavia, Moiola, Lucia, Naldi, Paola, Pane, Chiara, Perrone, Patrizia, Pizzorno, Matteo, Pozzilli, Carlo, Prosperini, Luca, Rezzonico, Monica, Rovaris, Marco, Salemi, Giuseppe, Salvetti, Marco, Santuccio, Giuseppe, Scarpazza, Cristina, Scarpini, Elio, Sessa, Edoardo, Solaro, Claudio, Tabiadon, Giulia, Tortorella, Carla, Trojano, Maria, Valentino, Paola +49 morecore +4 more sourcesEffect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension [PDF]
, 2018 Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or ...Achiron, Anat, Airas, Laura, Al Khedr, Abdullatif, Alvarez Cermeño, Jose Carlos, Arnold, Douglas L, Ayuso, Guillermo Izquierdo, Bandari, Daniel, Bartholomé, Emmanuel, Baum, Karl, Bergamaschi, Roberto, Berger, Joseph, Berthele, Achim, Bhan, Virender, Blevins, Gregg, Boyko, Alexey, Brassat, David, Brochet, Bruno, Brunet, Donald, Cadavid, Diego, Camac, Ann, Campbell, Nolan, Camu, William, Chang, Ih, Chefranova, Zanna, Cohan, Stanley, Comi, Giancarlo, Conway, Jill, Cottone, Salvatore, Czarnecki, Maciej, D'Hooghe, Marie, Debouverie, Marc, Devonshire, Virginia, Deykin, Aaron, Drozdowski, Wieslaw, Duddy, Martin, Dufek, Michal, Duquette, Pierre, Edwards, Keith, Elovaara, Irina, Eralinna, Juha-Pekka, Escartin, Antonio, Evdoshenko, Evgeny, Fabian, Michelle, Faiss, Juergen, Fernandez, Oscar Fernandez, Flachenecker, Peter, Florin, Jack, Forrestal, Fiona, Frederiksen, Jette, Freedman, Mark, Freedman, Mark S, Freedman, Steven, Frequin, Stephan, Fryze, Waldemar, Gairin, Xavier Montalban, Garcia-Merino, Antonio, Garwacki, Dennis, Goldman, Myla, Goldman, Myla D, Gran, Bruno, Grand'Maison, François, Grimaldi, Luigi, Gunnarsson, Martin, Hardiman, Orla, Harrison, Daniel, Harrower, Timothy, Hartung, Hans-Peter, Havrdová, Eva Kubala, Havrdová, Eva Kubala, Hernandez Perez, Miguel Angel, Herrman, Craig, Hertmanowska, Hanka, Ho, Pei-Ran, Hobart, Jeremy, Hohlfeld, Reinhard, Huang, Deren, Hupperts, Raymond, Ilkowski, Jan, Jacques, François, Javed, Adil, Jeffery, Douglas, Jeffery, Douglas, Kamin, Stephen, Kaminska, Anna, Kanovsky, Petr, Kant, Matthias, Kapoor, Raju, Kapoor, Raju, Karussis, Dimitrios, Katsamakis, George, Khabirov, Farit, Khatri, Bhupendra, Killestein, Joep, Klodowska-Duda, Gabriela, Krumbholz, Markus, Lallana, José Meca, Langer-Gould, Annette, Lapierre, Yves, Laplaud, David, Lassek, Christoph, Lebrun Frenay, Christine, Lee, Liesly, Lee, Martin, Lucas, Nisha, Lycke, Jan, Lynch, Sharon, Maciejowski, Maciej, Maeurer, Mathias, Mancardi, Giovanni Luigi, Martin, Claes, Massacesi, Luca, Mattison, Paul, Mattson, David, Mcguigan, Christopher, Meuth, Sven, Mikol, Dan, Miller, Aaron, Miller, Tamara, Miravalle, Augusto, Morra, Vincenzo Brescia, Morrow, Sarah, Moses, Harold, Motta, Ewa, Muley, Suraj, Napier, James, Nicholas, Richard, Nielsen, Allen, Nocentini, Ugo, Oreja-Guevara, Celia, Pachner, Andrew, Pandolfo, Massimo, Pardo, Gabriel, Pearson, Owen, Pelletier, Jean, Petersen, Thor, Picone, Maryann, Piehl, Fredrik, Podemski, Ryszard, Potemkowski, Andrzej, Rashid, Waqar, Ravnborg, Mads, Robertson, Derrick, Rog, David, Rog, Teresa, Roshanisefat, Homayoun, Royal, Walter, Saiz Hinarejos, Albert, Salvetti, Marco, Sarasoja, Taneli, Scarpini, Elio, Schrijver, Hans, Sellebjerg, Finn, Sellebjerg, Finn, Selmaj, Krzysztof, Sharrack, Basil, Sheppard, Christopher, Silber, Eli, Sivertseva, Stella, Sola, Patrizia, Steiner, Deborah, Stelmasiak, Zbigniew, Stepien, Adam, Stetkarova, Ivana, Sundstrom, Peter, Talabova, Marika, Tedeschi, Gioacchino, Thrower, Ben, Trojano, Maria, Turner, Ben, Tutaj, Andrzej, Twyman, Cary, Van Dijl, Ronald, van Munster, Erik, Van Wijmeersch, Bart, Vermersch, Patrick, Vukusi, Sandra, Waubant, Emmanuelle, Wendt, Jeanette, Williams, Anna, Woolmore, John, Yadav, Vijayshree, Yakupov, Eduard, Yeung, Michael, Young, Carolyn, Yu, Bei, Zabad, Rana, Zaborski, Jacek, Zaffaroni, Mauro, Zarelli, Greg, Ziemssen, Tjalf +189 morecore +3 more sourcesDynamic changes of mmp-9 plasma levels correlate with jvc reactivation and immune activation in natalizumab-treated multiple sclerosis patients [PDF]
, 2019 The aim of the study was to investigate the changes of matrix metalloproteinase (MMP)-2 and MMP-9 plasma levels during natalizumab treatment and their correlation with JC virus (JCV) reactivation and T-lymphocyte phenotypic modifications in peripheral ...Ciardi, Maria Rosa, Cortese, Antonio, D’Agostino, Claudia, Francia, Ada, Frontoni, Marco, Iannetta, Marco, Latronico, Tiziana, Liuzzi, Grazia Maria, Mastroianni, Claudio Maria, Pati, Ilaria, Pietropaolo, Valeria, Pontecorvo, Simona, Prezioso, Carla, Vullo, Vincenzo, Zingaropoli, Maria Antonella +14 morecore +3 more sourcesJC virus-DNA detection is associated with CD8 fffector accumulation in peripheral blood of patients with multiple sclerosis under natalizumab treatment, independently from JC virus serostatus [PDF]
, 2018 Although natalizumab (anti-α4 integrin) represents an effective therapy for relapsing remitting multiple sclerosis (RRMS), it is associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML), caused by the polyomavirus ...Anzivino, Elena, Ciardi, Maria R., Cortese, Antonio, D’Abramo, Alessandra, Francia, Ada, Frontoni, Marco, Iannetta, Marco, Lichtner, Miriam, Mastroianni, Claudio M., Morreale, Manuela, Oliva, Alessandra, Pietropaolo, Valeria, Pontecorvo, Simona, Prezioso, Carla, Rodio, Donatella Maria, Vullo, Vincenzo, Zingaropoli, Maria A. +16 morecore +3 more sources
